DauresM, IdrissouM, JudesG, et al. (2018). A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2. Oncotarget, 9, 23413–23425.
2.
DauresM, NgolloM, JudesG, et al. (2016). The JMJD3 histone demethylase and the EZH2 histone methyltransferase in prostate cancer. OMICS, 20, 123–125.
3.
DzoboK. (2019). Epigenomics-guided drug development: Recent advances in solving the cancer treatment “jigsaw puzzle”. OMICS, 23, 70–85.
4.
MishraDK, ChenZ, WuY, et al. (2010). Global methylation pattern of genes in androgen sensitive and androgen independent prostate cancer cells. Mol Cancer Ther, 9, 33–45.
5.
TakayamaK. (2019). Splicing factors have an essential role in prostate cancer progression and androgen receptor signaling. Biomolecules, 9, 7–8.
6.
YuG, LeeY-C, ChengC-J, et al. (2015). RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res MCR, 13, 348348at.
